Agilent Award LabCentral Golden Ticket to Trilogy Sciences

The Column

The Column, The Column-06-04-2020, Volume 16, Issue 6
Pages: 5

Agilent Technologies Inc. has announced that biotech start-up Trilogy Sciences has been awarded an Agilent Golden Ticket at LabCentral, a leading biotech innovation hub based in Cambridge, Massachusetts,

Agilent Technologies Inc. has announced that biotech start-up Trilogy Sciences has been awarded an Agilent Golden Ticket at LabCentral, a leading biotech innovation hub based in Cambridge, Massachusetts, USA. LabCentral is a shared laboratory space designed as a launchpad for high-potential life sciences and biotech start-ups. The Golden Ticket provides funding for one lab bench space for a year.

“As part of Agilent and LabCentral’s shared commitment to advancing health sciences and early-stage biotechnology companies, we are thrilled to provide Trilogy with an Agilent Golden Ticket,” said Darlene Solomon, senior vice president and chief technology officer, Agilent Technologies.

Trilogy Sciences’ mission is to develop therapeutics for untreatable diseases by applying cutting-edge chemical biology, including new methodologies to rapidly synthesize and screen for hyper-effective drugs to combat recurrent breast, brain, and lung cancers.

Agilent is a platinum sponsor of LabCentral and has equipped the shared laboratory workspace with a variety of Agilent’s technologies, including a high-resolution mass spectrometry system, and a cell analysis extracellular flux (XF) analyzer. The sponsorship includes the Golden Ticket, which represents one year of bench space for a scientist, including the benefit of LabCentral’s shared infrastructure and services.

For more information please visit: www.agilent.com